Farmas USA

Ok gracias.... quiero pensar algo así.

Para mi ya no es una opcion, esa parada la deje atras hace ya unos cuantos miles de $.

THLD

GERN , espectacular, 

ampliación de la original

November 30, 2015 at 08:00 AM EST

Chiasma Announces Addition of James R. Tobin and John F. Thero to Board of Directors

NEWTON, Mass., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Chiasma, Inc. (NASDAQ:CHMA), a late-stage biopharmaceutical company developing Mycapssa™ (octreotide capsules), an investigational oral drug for the maintenance therapy of adult patients with the orphan disease acromegaly, today announced that James R. Tobin and John F. Thero have joined the company's Board of Directors.

Mr. Tobin, formerly president and CEO of Biogen, Inc. and Boston Scientific Corporation, will serve as a member of the Audit Committee. Mr. Thero, President and CEO of Amarin Corporation (NASDAQ:AMRN), will serve as chairman of the Audit Committee.

"We are excited to add these experienced, highly regarded biotech leaders to Chiasma's Board of Directors at this important stage in our development," said Mark Leuchtenberger, Chief Executive Officer of Chiasma. "Both Jim and John have deep operational and commercial experience on an international level, and their business acumen and leadership will be invaluable to the Board as we continue to build out our infrastructure and position the company for long-term success."

Mr. Tobin was most recently President and CEO of Boston Scientific Corporation from March 1999 to July 2009. Prior to Boston Scientific, he served as President and CEO of Biogen from February 1997 to December 1998, and President and COO of Biogen from February 1994 to February 1997. Prior to joining Biogen, Mr. Tobin was with Baxter International Inc., where he served as President and COO from 1992 to 1994, as Executive Vice President from 1988 to 1992, and in various management positions prior to 1988. Mr. Tobin served as lieutenant in the U.S. Navy from 1968 to 1972. He has been a Director of multiple private and public life science firms and hospitals, and currently serves on the boards of several private companies as well as Globus Medical, Inc. (NYSE:GMED) and Oxford Immunotec Global PLC (NASDAQ:OXFD). Mr. Tobin earned an M.B.A. from Harvard Business School and an A.B. from Harvard College.

Mr. Thero joined Amarin in November 2009 and has more than 20 years of senior financial and operational management experience, including more than 15 years supporting the growth of life science companies. Mr. Thero became President and CEO of Amarin in 2014 after previously serving as the company's President and initially as the company's Chief Financial Officer. Prior to Amarin, Mr. Thero was at ViaCell, Inc., where as Chief Financial Officer he helped guide the company to its successful sale to PerkinElmer, and Abiomed, Inc., where he held multiple positions, including Senior Vice President of Business Operations and Chief Financial Officer, and helped manage the company's transition from a development-stage company into a commercial entity. Mr. Thero began his professional career at Arthur Andersen LLP.

Mi sistema es claro, me pide que pondere a 3,45 y que no venda con 10% de perdida.....con lo cual , metida orden de otras 2000 a 3,45.....vamos que lejos de saltar del barco , le doy otra oportunidad .....😉

Correcto, la hundieron con un estudio hasta 1$ y la subieron a 10 con el segundo.

CYTX

preclinical data demonstrating that Cytori Cell Therapy can promote burn wound healing via topical spray delivery, achieving similar effects to local injection. The option for spray delivery expands the potential utility and offers greater ease of use for Cytori Cell Therapy in the burn setting. The study was performed with support from the Biomedical Advanced Research and Development Authority (BARDA), and is described in a paper entitled “Adipose-Derived Regenerative Cell Therapy for Burn Wound Healing: A Comparison of Two Delivery Methods” (Foubert P. et al. DOI: 10.1089/wound.2015.0672) now available online (http://online.liebertpub.com/doi/abs/10.1089/wound.2015.0672).

http://ir.cytori.com/investor-relations/News/news-details/2015/Topical-Administration-of-Cytori-Cell-Therapy-Effective-in-Thermal-Burn-Approach/default.aspx

GILD

Fuera a 106 desde los 102,9. Me ha saltado el stop. Algo es algo, pero mal jugado.

Si me dejan al ceo 5 minutos cuando defendio y presentó aquello aún comería con pajita, en un gráfico a 3 años se ve muy claro lo que hicieron, Este fin de semana se me paso por la cabeza la misma idea que comentas framus, además son dos los estudios que presenta Thld, no?